XOMA Corporation (Nasdaq: XOMA) unveiled its interleukin-2 (IL-2) monoclonal antibody program, a series of novel agents from its scientific discovery ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE